Genetic Analysis: Standardizing the Future of Microbiome Diagnostics - Analyst Group

Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for diagnostic analysis of microbiomes — the collection of microorganisms in the body that support digestion, immunity, and overall health. The human microbiome market is growing fast, as its importance for health has been increasingly recognized, yet the field has so far lacked standardization. The GA-map® platform aims to standardize microbiome diagnostics, which is expected to generate high long-term sales growth with a CAGR of 39% from 2024-2028. With an applied EV/S multiple of 1.4x on 2027’s estimated sales of NOK 46.4m and a discount rate of 13.4%, a potential present value per share of NOK 1.0 is derived in a Base scenario.

Länk till analysen i sin helhet: https://analystgroup.se/analyser/genetic-analysis/